Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS

Referee #1
In this manuscript Biesemann et. al report a new FACS -MS approach to determine the excitatory synapato-proteome while the approach holds some promise the current manuscript falls quite short of the intended goal. The authors previously reported a knock-in VGLUT1 VENUS mouse model and in this manuscript they attempt to couple this mouse with proteomic mass spectrometry. While the manuscript has a few bright spots it would require a very major improvement to be worthy for EMBO Resource. While the approach seems promising and well documented the "new biology" uncovered and high degree of background protein detection significantly lowers my interested. Moreover the authors make little attempt to address the completeness of their analysis beyond a weak comparison with mRNA expression data. Overall the work hold promise but with the data presented it is not sufficiently matured, if after much revision it may be worth considering for EMBO again at a much later date.
MAJOR CONCERNS: 1. In general the figures are occupied with too much description of the technique and not enough new biology which it uncovered even for a resource. 2. While the paper is well written and thought-through a major hole is the missing evidence for the "completeness" of the analysis. Mass spectrometers can always detect some proteins but it is completely unclear how well covered the analysis presented here truly is. In the current form the authors frame the study to determine the excitatory synapto-proteome but never show they have accomplished this. 3. The approach is cool but is still just an enrichment, it maybe that excitatory synapto-proteomes may never be fully determined with confidence in this way. Rather with stable isotope labeling, N15 or heavy-Lys labeled samples are mixed before syaptosome purification and in this way with targeted paradigms can best determine regulated proteomes with requiring biochemical enrichment for the conclusions. 4. Overall too many cropped gels with white bars and low N's for replicates and the EM synaptosome data is not great. This makes me wish the authors had waited to submit till the work was further developed. 5. Detailed description of Mass spectrometry operation is lacking, techniques are a bit dated and not the current standard. How many MS/MS per MS? What was the MS1 M/Z scanning range? Comments like "Bold Red peptides" as a column header in Sup Table one sounds very amateur and impossible for readers for grasp unless they are Mascot users and even then should be more articulately described. How was the false discovery rate controlled in the search? MINOR CONCERNS: 1. Text such as "pure to near homogeneity, and most contaminants that are found in conventional synaptosome preparations are strongly depleted." -Sounds problematic. 2. NL data is potentially interesting but again not even number of replicates and low N's. GluR stuff could be of interest but the data is not quite there. 3. The number of the peptides and S.C.s are quite low for very well characterized excitatory synaptic proteins seeing the authors have the valuabe KI mouse why not scale up to boost the recovery? Sup. Table one contains hundreds of proteins which are not likely to be specific for excitatory synapses. I am surprised again by the low level of recovery for AMPAr sub-unitis. 4. Comparing neuronal mRNA expression does not add much insight or QC power. 5. Figure 6 data on FXYD6 and Tpd52 would have been awesome but the images presented makes the reader gather these proteins are highly abundant and potentially non-specific. It would have helped if there were inhibitory synapses staining to further the point of specificity.
Referee #2
Christoph et al use a novel Fluorescence Activated Synaptosome Sorting(FASS) method to purify and analyze specific subpopulations of isolated synapses (synaptotsomes).This manuscript contains important information and I is suitable for publication in EMBO J, provided some revisions are made.
The first part of the manuscript regarding the standard protocol of FASS is clear and valid. The second part supports the validation of FASS sample quality and proved that the FASS method in this manuscript is consistent with previous published papers. Figure 4 and 5 demonstrate that FASS is better than previous methods for analyzing glutamatergic synaptic proteins. However, it is important to note that the FASS has limitations for analyzing GABAergic synaptic proteins which may greatly affect the applicability of this method. The last part of this manuscript provides 2 novel proteins which are never reported as synaptic proteins: FXYD6 and Tpd52, and from these findings, the authors prove that this method has a huge advantage for high resolution biochemical analyses of glutamatergic synapses. I have just a few minor concerns that should be addressed:
1. Figure 2 seems to impair the flow of the study (and does not seem to be particularly important for the whole manuscript), so the authors might consider some reorganization by putting this figure into the supplemental materials, leading to more coherent story. Figure 4 the authors used mRNA expression profiles to prove that their systematic comparative analyses of the protein composition of sorted and unsorted synaptosomes samples using mass spectrometry-based protein identification is consistent. But only a small subset of data on this front are shown; a complete table comparing mRNA expression profiles with the mass spectrometry analyses would be helpful. It also be helpful to include more blots to confirm the mass spec results, if possible. This raises another key point: why is the threshold for enrichment set to 2-fold? As presented, that value seems arbitrary. 3. It will be better to classify, or group together (e.g. as cytoskeletal, exocytosis, endocytosis, etc.), the 163 enriched proteins in FASS samples.
In
The authors may want to refer to the following article: Molecular profiling of synaptic vesicle docking sites reveals novel proteins but few differences between glutamatergic and GABAergic synapses. Neuron. 2013 Apr 24;78(2):285-97. doi: 10.1016/j.neuron.2013.02.027
Referee #3
The manuscript describes a novel technical approach to obtain information about what proteins are enriched in nerve terminals. This in many ways is directly complementary to landmark work published 7 years ago by the Jahn group that cataloged as accurately as possible the protein makeup of synaptic vesicles.Knowing what is enriched in the volume that surrounds the vesicles, i.e. the nerve terminal, is a question of equally interest. The biggest advance of this work is to refine the knowledge about particular synapses, defined by the type of vesicular neurotransmitter transporter present. Using KI mice carrying tagged vGlut1 they are able to sort synaptosomes that are positive for this. The work is elegant and carried out with considerable technical expertise. The paper is suitable as a resource type of paper as it is a first cataloging of this type and the data will no doubt be of interest for years to come. I have only very minor comments: the identity of the new candidates (FXYD6 and Tpd52) is intriguing but I do worry about being overconfident in immunolocalization until the staining has been validated in some way -this is really to say that some caution should be emphasized in viewing the subcellular localization. This work will be especially exciting if one manages in the future to carry this out to enrich in the other transporter types and compare. That is obviously beyond the scope of this manuscript. Referee #1
In this manuscript Biesemann et. al report a new FACS -MS approach to determine the excitatory synapato-proteome while the approach holds some promise the current manuscript falls quite short of the intended goal. The authors previously reported a knock-in VGLUT1 VENUS mouse model and in this manuscript they attempt to couple this mouse with proteomic mass spectrometry. While the manuscript has a few bright spots it would require a very major improvement to be worthy for EMBO Resource. While the approach seems promising and well documented the "new biology" uncovered and high degree of background protein detection significantly lowers my interested.
Moreover the authors make little attempt to address the completeness of their analysis beyond a weak comparison with mRNA expression data. Overall the work hold promise but with the data presented it is not sufficiently matured, if after much revision it may be worth considering for EMBO again at a much later date.
MAJOR CONCERNS: 1. In general the figures are occupied with too much description of the technique and not enough new biology which it uncovered even for a resource.
The referee is right in mentioning that we provide extensive methodological descriptions. Indeed, the aim of our contribution was to provide two new resources to the community. The first achievement of resource character is the methodology to enrich VGLUT1 synaptosomes to unprecedented purity. This provides a new exciting perspective for synaptosome-based studies on synapse structure and function, and a strong methodological basis for cell biologists and biochemists interested in fluorescence sorting of micro-particles and organelles in general.
The second achievement of resource character is the proteomic comparison of sucrose synapstosomes and FASS VGLUT1 synaptosomes. We identified more than 500 proteins that are differentially segregated between sucrose synaptosomes, which are an impure mixture of different synaptosome types, and FASS VGLUT1 synaptosomes. To further extract information from this dataset, we now sorted the 163 proteins enriched 2 fold or more according to subcellular localization and cellular function categories (Table S4 and Fig. 5D ,E; P9 L1-9; P13 L33-34 -P14 L1-3; supplemental methods p5). Our screening identified 22 proteins of unknown cellular function, while others are of known function or subcellular localization but unanticipated as synaptic proteins. Among the latter, TPD52 and FXYD6 were further studied and were confirmed to be strongly expressed at excitatory synapses with several independent experimental approaches. Respective putative functions in membrane trafficking and membrane potential regulation make TPD52 and FXYD6 attractive for further investigations, which are beyond the scope of this report. Altogether, we hope that these improvements will provide readers with a better access to pertinent proteins of interest for their research.
2. While the paper is well written and thought-through a major hole is the missing evidence for the "completeness" of the analysis. Mass spectrometers can always detect some proteins but it is completely unclear how well covered the analysis presented here truly is. In the current form the authors frame the study to determine the excitatory synapto-proteome but never show they have accomplished this.
This point is well taken. It is true that we do not have any evidence for "completeness" of our analysis. However, the number of proteins identified in our study correlates very well with the number of proteins identified in other proteomics studies of synaptosomes (e.g. Banerjee et al, Exp Neurol 236, 298-306, 2012 ). In addition, our analysis was conducted on a very fast and sensitive instrument (Orbitrap LTQ XL), allowing deep coverage even with low abundance samples. Furthermore, our approach is based on a sample of only moderate complexity, in which VGLUT1 bearing particles are highly enriched and others highly depleted. We therefore believe that to a great extend our analysis represents the proteins present in VGLUT1 synaptosomes.
Because we did not directly check the completeness of our proteomic analysis, we changed the title of our manuscript accordingly. Despite this concession, we feel that our study provides important new insights and resources that deserve publication in EMBO Journal (see comment to point 1 above).
3. The approach is cool but is still just an enrichment, it maybe that excitatory synapto-proteomes may never be fully determined with confidence in this way. Rather with stable isotope labeling, N15 or heavy-Lys labeled samples are mixed before syaptosome purification and in this way with targeted paradigms can best determine regulated proteomes with requiring biochemical enrichment for the conclusions.
The reviewer is right that our Fluorescence Activated Synaptosome Sorting (FASS) strategy is an enrichment strategy, which we combined with MS-based spectral counting for quantification. However, to our knowledge no better sample of VGLUT1 synaptosomes has been described before. As pointed out in the introduction (P3 Para2), actual synaptosomes represent at most 50% of the sucrose samples. Among these, roughly 80% can be assumed to be glutamatergic in forebrain samples. In cortical SV preparations from VGLUT1 KOs, 80% of the glutamate transport activity is lost while the 20% remaining arise from VGLUT2 (Fremeau et al., science, 2004) , indicating that some 80% of glutamatergic synaptosomes are likely pure VGLUT1 synaptosomes. Therefore, VGLUT1 synaptosomes should roughly represent 30-35% of the sucrose samples. Through FASS of VGLUT1 venus sucrose samples we enrich VGLUT1 more than 2.5 fold, while contaminants such as VAchT (cholinergic particles), PLP (myelin) or GLT1 (astrocytic membranes) are 10 fold depleted. Thus, we think that our FASS method leads to an enrichment of VGLUT1 synaptosome particles to near homogeneity. The sensitivity of current MS/MS devices makes it critical to provide the cleanest and most homogeneous sample possible, and we believe to have achieved this through FASS sorting of VGLUT1 synaptosomes. Changes in the text were implemented to better illustrate this reasoning (P4 L8 L10; P5 L8-11; P11 L3 L7 L25-27; P12 L2).
As indicated by the reviewer, the use of stable isotope labeling would have improved the accuracy of our quantification. However, we expected that spiking control and FASS samples with heavy isotope labeled brain or cell line samples would not significantly improve the accuracy of our quantification, and the tools to feed our VGLUT1 Venus mice with isotope labeled synthetic food were not commercially available when our proteomics work was conducted. Discussion was modified to acknowledge this point (P15L18-21)
4. Overall too many cropped gels with white bars and low N's for replicates and the EM synaptosome data is not great. This makes me wish the authors had waited to submit till the work was further developed.
The point raised by this referee is well taken and is similar to comment 2 of referee 2. We would like to remind the referees of the fact that one day of FASS sorting allows to blot a maximum of 3 SDS-PAGE lanes, each with 0.5 µg of protein that have to be titrated by silver staining prior to Western blot analysis. This has led us to crop blots of high quality when relevant lanes were not side-by-side. At no point did we 'fuse' lanes from different blots or different exposures. We feel that this is sufficiently prudent and stringent given the complexity of the experiments -it is legitimate to compare these cropped images as they originate from the same blot. Nevertheless, more markers were tested. The current version of the paper was updated with 7 additional markers tested by Western blot, mostly in independent triplicates (VAMP2, Rab3a, Dynamin 1, and Clathrin LC, Fig.  3 ; PSD95, Synaptopodin, GluA1, Fig. 4 ). Some displays of other markers were updated (VGLUT1 venus and SynapsinI, Fig. 3; GluN1, Fig. 4 ). Remarkably, our new data on PSD95 and synaptopodin allow us to clearly define the postsynaptic part that is contained in the synaptosome. We find that PSD95 is copurified by FASS whereas Synaptopodin is depleted, indicating that PSDs (containing PSD95) are part of synaptosomes whereas the spine neck (containing the spine apparatus with synaptopodin) is not. Thus, FASS purified synaptosomes allow for the segregation of synaptic and extrasynaptic components, including receptors (see data on GluN2B, Fig. 4I,J) . Corresponding results, discussion, legends, and methods were updated (P6 L6-10; P7 L17-20 L32; P8 L16-22; P12 L15-19; P13 L1-2; P17 L23-33).
Detailed description of Mass spectrometry operation is lacking, techniques are a bit dated and not the current standard. How many MS/MS per MS? What was the MS1 M/Z scanning range?
Comments like "Bold Red peptides" as a column header in Sup Table one sounds very amateur and impossible for readers for grasp unless they are Mascot users and even then should be more articulately described. How was the false discovery rate controlled in the search?
We apologize for the missing details in the MS part of materials and methods. The details have been included in the revised manuscript (PXX LYY). The problematic column labels of the tables were changed.
MINOR CONCERNS:
1. Text such as "pure to near homogeneity, and most contaminants that are found in conventional synaptosome preparations are strongly depleted." -Sounds problematic.
As stated above, the current FASS sample enriches VGLUT1 2.5 fold and depletes many wellknown contaminants by 5 to 10 fold (see comments to point 3 above). Thus we do think that FASS enriches synaptosomes to near homogeneity. However, the relevant text passages were slightly toned down to avoid any overstatements (PXX LYY).
2. NL data is potentially interesting but again not even number of replicates and low N's. GluR stuff could be of interest but the data is not quite there.
NL data were generated in triplicates, except for the well-characterized inhibitory synapse isoform NL2 (n=2), which is depleted as expected.
The GluR data were improved with the addition of GluA1 quantification and a better display of GluN1 data (Fig. 4; P7 L32 ). Our conclusions are further supported by a better characterization of the postsynaptic part of synaptosomes via quantification of synaptopodin by Western blot and MS (Fig. 4E,F and 5B ; P7 L17-20) (see also comments to point 4 above).
3. The number of the peptides and S.C.s are quite low for very well characterized excitatory synaptic proteins seeing the authors have the valuabe KI mouse why not scale up to boost the recovery? Sup. Table 1 contains hundreds of proteins which are not likely to be specific for excitatory synapses. I am surprised again by the low level of recovery for AMPAr sub-units.
The current experiment was performed with 8 µg of protein, which corresponds to the accumulation of 9 days of sorting each time using fresh S-synaptosome preparations. It is indeed a current limitation of the method that it is difficult to sort more than 2 µg of proteins per day. Hence further upscaling of the procedure was not possible.
Of note, Table S1 displays the S-synaptosome proteome, Table S2 displays the FASS synaptosome proteome, and Table S3 displays the comparative changes for more than a thousand of the proteins accurately identified in our samples. The new Table S4 presents the classification of proteins that are significantly enriched in the FASS sample by functional and localization categories. Therefore, Table S1 is indeed expected to contain many proteins unrelated to VGLUT1 synapses (due to the impurities in the S-synaptosomes).
Protein Name
Mascot Protein Score glutamate receptor, ionotropic, AMPA 2 isoform 2 1943 glutamate receptor, ionotropic, AMPA 2 isoform 3 1896 glutamate receptor, ionotropic, AMPA 4 isoform 1 501 glutamate receptor, ionotropic, AMPA 4 isoform 2 611 glutamate receptor, ionotropic, AMPA1 (alpha 1) isoform 2 439 glutamate receptor, ionotropic, AMPA3 862
Above, we show the Mascot scores for AMPA receptor subunits from Table S2 . The absence of extrasynaptic post-synaptic compartments and a likely under-representation of intracellular pools of receptors in the VGLUT1 FASS sample may explain the limited co-enrichment of receptors as compared to presynaptic markers.
Comparing neuronal mRNA expression does not add much insight or QC power.
This meta-analysis was intended to support the reliability of our hits. We feel that the dataset is relevant in this context and opted to leave it in the manuscript. Figure 6 data on FXYD6 and Tpd52 would have been awesome but the images presented makes the reader gather these proteins are highly abundant and potentially non-specific. It would have helped if there were inhibitory synapses staining to further the point of specificity.
5.
GAD67 labeling with FXYD6 is presented in Figure S3 and confirms weak or no colocalization of FXYD6 with GABAergic neurons. In the revised version of the paper, we included Figure S4 , where an analysis of TPD52 colocalisation with GAD65 and MAP2 is shown. Colocalisation of TPD52 with GAD65 is very low as compared to that seen with VGLUT1. (Fig. S4 , P10 L4-8; supplemental text P1 and P6)
Referee #2
The first part of the manuscript regarding the standard protocol of FASS is clear and valid. The second part supports the validation of FASS sample quality and proved that the FASS method in this manuscript is consistent with previous published papers. Figure 4 and 5 demonstrate that FASS is better than previous methods for analyzing glutamatergic synaptic proteins. However, it is important to note that the FASS has limitations for analyzing GABAergic synaptic proteins which may greatly affect the applicability of this method. The last part of this manuscript provides 2 novel proteins which are never reported as synaptic proteins: FXYD6 and Tpd52, and from these findings, the authors prove that this method has a huge advantage for high resolution biochemical analyses of glutamatergic synapses. I have just a few minor concerns that should be addressed: 1. Figure 2 seems to impair the flow of the study (and does not seem to be particularly important for the whole manuscript), so the authors might consider some reorganization by putting this figure into the supplemental materials, leading to more coherent story.
The point is well taken. However, we feel that our new method is a resource in its own right and deserves to feature prominently in the manuscript. We therefore chose to keep Fig. 2 in the main text and hope this will be OK with this referee. Figure 4 the authors used mRNA expression profiles to prove that their systematic comparative analyses of the protein composition of sorted and unsorted synaptosomes samples using mass spectrometry-based protein identification is consistent. But only a small subset of data on this front are shown; a complete table comparing mRNA expression profiles with the mass spectrometry analyses would be helpful. It also be helpful to include more blots to confirm the mass spec results, if possible.
In
The current version of the paper was updated with 7 additional markers tested by Western blot, mostly in independent triplicates (VAMP2, Rab3a, Dynamin 1, and Clathrin LC, Fig. 3 ; PSD95, Synaptopodin, GluA1, Fig. 4 ). Some displays of other markers were updated (VGLUT1 venus and SynapsinI, Fig. 3; GluN1, Fig. 4 ). Remarkably, our new data on PSD95 and synaptopodin allow us to clearly define the postsynaptic part that is contained in the synaptosome. We find that PSD95 is copurified by FASS whereas Synaptopodin is depleted, indicating that PSDs (containing PSD95) are part of synaptosomes whereas the spine neck (containing the spine apparatus with synaptopodin) is not. Thus, FASS purified synaptosomes allow for the segregation of synaptic and extrasynaptic components, including receptors (see data on GluN2B, Fig. 4I,J) . Corresponding results, discussion, legends, and methods were updated (P6 L6-10; P7 L17-20 L32; P8 L16-22; P12 L15-19; P13 L1-2; P17 L23-33).
As regards more mRNA data, we now provide a new version of Table S3 , in which we show the mRNA expression data for all genes that could be matched with the dataset of Cahoy et al (J Neurosci 28, 264-278, 2008) .
This raises another key point: why is the threshold for enrichment set to 2-fold? As presented, that value seems arbitrary.
Although often used in related studies, a threshold of 2 fold change is indeed arbitrary. We felt very comfortable with this threshold as it ensures stringency in the selection of proteins enriched in VGLUT1 synaptosomes.
